ResMed Inc (RMD)vsSTAAR Surgical Company (STAA)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
STAA
STAAR Surgical Company
$19.19
+1.16%
HEALTHCARE · Cap: $867.46M
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 2154% more annual revenue ($5.40B vs $239.44M). RMD leads profitability with a 27.5% profit margin vs -33.6%. STAA appears more attractively valued with a PEG of 0.76. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
STAA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Intrinsic value data unavailable for STAA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
18.1% revenue growth
Areas to Watch
No major concerns identified
Smaller company, higher risk/reward
Weak financial health signals
ROE of -21.7% — below average capital efficiency
Earnings declined 10.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : STAA
The strongest argument for STAA centers on Debt/Equity, PEG Ratio, Price/Book. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : STAA
The primary concerns for STAA are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
RMD profiles as a mature stock while STAA is a growth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.05 — expect wider price swings.
STAA is growing revenue faster at 18.1% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 42/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?